<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Collection:</title>
  <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46273" />
  <subtitle />
  <id>http://dspace.bsuedu.ru/handle/123456789/46273</id>
  <updated>2026-04-07T14:06:47Z</updated>
  <dc:date>2026-04-07T14:06:47Z</dc:date>
  <entry>
    <title>Immune-metabolic genesis of pathological processes</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46327" />
    <author>
      <name>Zemskov, A. M.</name>
    </author>
    <author>
      <name>Berezhnova, T. A.</name>
    </author>
    <author>
      <name>Zemskova, V. A.</name>
    </author>
    <author>
      <name>Dyadina, K. S.</name>
    </author>
    <author>
      <name>Kulintsova, Y. V.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46327</id>
    <updated>2022-04-25T00:06:50Z</updated>
    <published>2019-01-01T00:00:00Z</published>
    <summary type="text">Title: Immune-metabolic genesis of pathological processes
Authors: Zemskov, A. M.; Berezhnova, T. A.; Zemskova, V. A.; Dyadina, K. S.; Kulintsova, Y. V.
Abstract: This article deals with metabolic-immune processes at rest and under stress conditions, which, in turn, results in the development of immune-dependent and immune-associated disorders. The authors also analyzed metabolic effects of immunomodulators. Based on the analysis of the literature and own clinical and experimental data, the authors identified the ability of metabolic factors to regulate immunological processes</summary>
    <dc:date>2019-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>The study of the endothelial protective properties of the L-norvaline combination with mexidol in the simulation of L-NAME-induced NO deficiency</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46326" />
    <author>
      <name>Konovalova, E. A.</name>
    </author>
    <author>
      <name>Chernomortseva, E. S.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46326</id>
    <updated>2022-04-25T00:04:55Z</updated>
    <published>2019-01-01T00:00:00Z</published>
    <summary type="text">Title: The study of the endothelial protective properties of the L-norvaline combination with mexidol in the simulation of L-NAME-induced NO deficiency
Authors: Konovalova, E. A.; Chernomortseva, E. S.
Abstract: The endothelium is considered as a target for the prevention and treatment of pathological processes leading to cardiovascular diseases. A combination of L-norvaline at a dose of 10 mg/kg and mexidol at a dose of 60 mg/kg against the background of L-NAME-induced endothelial dysfunction has a pronounced endothelial protective effect. The investigated drugs showed pronounced endothelial protective activity and can be recommended for further pre-clinical studies</summary>
    <dc:date>2019-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Correction of retinal ischemic injuries by using non-selective imidazoline receptor agonists in the experiment</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46325" />
    <author>
      <name>Levkova, E. A.</name>
    </author>
    <author>
      <name>Pazhinsky, A. l.</name>
    </author>
    <author>
      <name>Lugovskoy, S. S.</name>
    </author>
    <author>
      <name>Peresypkina, A. A.</name>
    </author>
    <author>
      <name>Bashuk, V. V.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46325</id>
    <updated>2022-04-25T00:05:35Z</updated>
    <published>2019-01-01T00:00:00Z</published>
    <summary type="text">Title: Correction of retinal ischemic injuries by using non-selective imidazoline receptor agonists in the experiment
Authors: Levkova, E. A.; Pazhinsky, A. l.; Lugovskoy, S. S.; Peresypkina, A. A.; Bashuk, V. V.</summary>
    <dc:date>2019-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46324" />
    <author>
      <name>Petrovsky, A. K.</name>
    </author>
    <author>
      <name>Smirnov, N. A.</name>
    </author>
    <author>
      <name>Vdovichenko, V. P.</name>
    </author>
    <author>
      <name>Fedorova, T. B.</name>
    </author>
    <author>
      <name>Kerbenev, E. E.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46324</id>
    <updated>2022-04-25T00:07:49Z</updated>
    <published>2019-01-01T00:00:00Z</published>
    <summary type="text">Title: Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis
Authors: Petrovsky, A. K.; Smirnov, N. A.; Vdovichenko, V. P.; Fedorova, T. B.; Kerbenev, E. E.
Abstract: The article notes that administering selank and semax to patients with tuberculosis would significantly reduce the number and severity of hepatotoxic reactions</summary>
    <dc:date>2019-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

